The Prolaris + AI Test sets a new standard by uniting clinical-pathological features, a proven molecular score, and AI-driven digital pathology into one comprehensive prognostic test for untreated patients with localized prostate cancer.1-5
Move beyond traditional, standalone measures toward approaches that bring together clinical insight, pathology, genomics, and AI to deliver a more complete understanding of disease biology — to help make complex decisions simpler and help avoid over or under treatment.
Myriad helped define the last decade of innovation by introducing the first genomic test to measure prostate tumor aggressiveness. Today, we are shaping the next era – setting a new standard that unites clinico-pathology, genomics, and now AI driven digital pathology to bring even greater confidence to prostate cancer management decisions.
Many patients eligible for active surveillance may safely defer definitive treatment for at least 10 years.6 That could mean more time living life, not managing treatment and side-effects.
The Prolaris + AI Test provides critical information to help support discussions with your intermediate-risk patients that are considering active surveillance.
Until now, no single test could help inform both if a patient is safe for AS and how intensive the AS protocol should be. The Prolaris + AI Test is the first and only genomic biomarker to provide two independent metrics specifically designed for active surveillance decisions. These metrics can help support discussions with your intermediate-risk patients that are considering active surveillance based on their individual risk.
Request a consultation or receive more information about integrating the Prolaris + AI Test into your clinical workflow.
By submitting this form, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may unsubscribe from these communications by following the unsubscribe link or the instructions provided in the communication we send. The information you submit is governed by our Privacy Notice and our website Terms of Use.
Contact Information
The Prolaris Test helps inform providers on potential changes to treatment plans.
In real-world clinical studies, the Prolaris Test influenced treatment decision changes in up to 65% of cases, helping clinicians to shift between active surveillance and definitive treatment based on individual risk.10,11
In a recent study, patients recommended for active surveillance by the Prolaris Test were twice as likely to choose it and had 50% higher 3-year durability compared to those recommended for definitive treatment.9
of patients tested with the Prolaris Test had a change in their treatment plan10,11
Identify which patients are appropriate for active surveillance
Because the Prolaris Test is the only biomarker with an AS threshold uniquely developed and validated in untreated patients, AS conversations with the untreated patient in front of you are more relevant and informed.12
The Prolaris Test outperforms other biomarkers in selecting active surveillance candidates.13
The Prolaris Test offers long-term prognostic risk that has been extensively validated across large, diverse cohorts to consistently identify appropriate candidates for active surveillance.4,7,13
A meta-analysis of 8,478 patients demonstrates independent prognostic performance for distant metastasis and prostate cancer-specific mortality (HR 2.28; 95% CI 1.98–2.62; p=9.1×10-9).4
Plan personalized AS follow-up
The Prolaris + AI Test helps confirm and personalize AS management5
Using existing digitized H&E slides, the Prolaris + AI Test informs AS planning by providing a tool to help determine intensity.5
AI-powered digital pathology reveals image‑based features of aggressiveness that may not be captured by routine clinical or pathological measures to independently predict the likelihood of higher Gleason score at next biopsy.5
In a validation study (N=296), the AI metric was a significant independent predictor of upgrade (OR 1.60 per SD; p=0.0003), while time‑to‑biopsy is not significant.5
Identify the patients who need definitive treatment and at what intensity
The Prolaris Test shows that those patients who fall below the multi-modal threshold do not benefit from intensifying treatment14
Establishing the multi-modal threshold
The Prolaris Test threshold was developed on approximately 1,500 intermediate and high-risk patients from two separate cohorts.
Validating patients prior to a multi-modal treatment
Patients were separated by those who received single-modal therapy versus those with multiple modes of treatment.
Guide the androgen deprivation therapy (ADT) conversation
Multiple groups with ADT variations evaluated for metastasis
The Multi-modal threshold was developed and double-validated across all outcomes to predict the risk of metastasis and determine which patients can appropriately forego ADT.14,15
At or below the multi-modal threshold(8.8% metastasis risk)
The Prolaris Test gives your patients personalized, shareable guidance and a simple “number-needed-to-treat” value.
Is ADT right for this patient?
Myriad Oncology™ helps customize your ordering process to meet your practice’s unique needs. With a physician-driven, conditional ordering model, Prolaris + AI testing can be initiated directly from the pathology lab — so you get critical results faster, right when treatment decisions are being made.
The beauty of conditional ordering? You stay in control — you decide which patients to test, and Myriad builds a workflow to support that.
Access detailed ordering instructions, specimen handling guidelines, and pathology resources to streamline every step of the testing process.
Imagine having a tool to clearly explain risks, thresholds, and treatment implications to your patients, step-by-step. The Prolaris + AI Test results are designed with patients and providers in mind to quickly answer pressing clinical questions, improving confidence in selecting the most appropriate management option.
AI doesn’t replace genomic testing; it enhances it. When combined with the Prolaris Test, AI adds independent, image-based insights that strengthen risk stratification. This comprehensive approach is uniquely developed and validated in untreated patients.5
Explore more tests and resources to support your prostate cancer patients.
This casual, yet educational, podcast is committed to keeping you informed on all things urology.
Hear from fellow clinicians on how the Prolaris+AI Test has changed the way they manage prostate cancer care.
This page includes AI generated images. Any similarity or resemblance to persons, living or dead, is purely coincidental.
References:
©2026 Myriad Genetics, Inc. Myriad Genetics, Myriad Oncology, Prolaris, MyRisk, and their respective logos, are either trademarks or registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions.